Overview

Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDD

Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety, tolerability and efficacy of desvenlafaxine succinate sustained release (DVS SR) in subjects with major depressive disorder.
Phase:
Phase 3
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Desvenlafaxine Succinate
Paroxetine